ETON vs SRPT
ETON: Eton Pharmaceuticals is a specialty drug company dedicated to acquiring and commercializing a diverse portfolio of therapies for rare diseases. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | ETON | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $49.30 | $18.56 | |
| Market cap | $1.4B | $2.0B | |
| Net margin FY2025, SEC XBRL | -5.8% | -32.5% | ETON higher |
| Gross margin FY2025, SEC XBRL | +53.5% | n/a | |
| Operating margin FY2025, SEC XBRL | -1.1% | -31.8% | ETON higher |
| ROE FY2025, SEC XBRL | -17.6% | -62.5% | ETON higher |
| ROA FY2025, SEC XBRL | -5.0% | -21.3% | ETON higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.60 | 0.55 | SRPT lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +104.9% | +15.6% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +55.5% | +33.1% | ETON higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.82 | 1.56 | |
| 1-year return as of 2026-10-21 close | +165.8% | -20.5% | ETON higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.